从临床瓶颈与研究现状探析中医药防治胆石症Exploring the prevention and treatment of cholelithiasis with traditional Chinese medicine: from clinical bottlenecks and current research status
张立平,魏骄阳
摘要(Abstract):
胆石症防治体系在“早期干预”与“预防复发”两个关键环节上存在明显薄弱——无症状患者仅采取生活方式干预,慢性保守治疗药物对胆色素结石疗效欠缺,各类手术后复发率较高且缺乏公认的防复发方案。现代医学之所以难以突破这些瓶颈,原因在于其对胆石形成的三大环节:胆汁成分异常、胆道动力障碍及胆道壁微环境改变均缺乏根本性干预手段。为此,该文选择胆总管结石复发作为切入点,该病种形成周期短、复发终点明确,既具有临床紧迫性,又为研究提供了理想窗口,系统梳理了其危险因素、分子机制及中西医防治现状。在此基础上发现,现有中医药研究虽已积累一定证据,但治法多侧重清热利湿、疏肝理气等“攻邪”之法,对取石术后虚证关注不足。该文介绍了作者团队针对这一空白开展的系列工作:证型研究揭示了脾虚证在术后患者中的核心地位,据此确立“健脾疏肝、清热利胆”治法并组方利胆消石合剂,临床与基础研究证实该方通过多靶点、多通路系统性改善成石环境。该文认为,中医药防治胆石症的价值,正在于填补关键阶段的临床空白,通过攻补兼施、肝脾同调,实现对胆石形成三大环节的系统性调节,为胆石症全程防治提供了一条中西医优势互补的新路径。
关键词(KeyWords): 胆石症;胆总管结石;防治并重;肝郁脾虚;疏肝健脾
基金项目(Foundation): 北京中医药大学基础科研业务费重点攻关项目(No:2020-JYB-ZDGG-138);北京中医药大学基础科研业务费揭榜挂帅项目(No:2023-JYB-JBZD-004)
作者(Author): 张立平,魏骄阳
参考文献(References):
- [1] 中国中西医结合学会消化系统疾病专业委员会.胆石症中西医结合诊疗专家共识(2025年)[J].中国中西医结合消化杂志,2025,33(3):242-251.
- [2] Lee BJH,Yap QV,Low JK,et al.Cholecystectomy for asymptomatic gallstones:Markov decision tree analysis[J].World J Clin Cases,2022,10(29):10399-10412.
- [3] Li WC,Huang PZ,Lei PR,et al.Risk factors for the recurrence of stones after endoscopic minimally invasive cholecystolithotomy in China:a meta-analysis[J].Surg Endosc,2019,33(6):1802-1810.
- [4] Wu Y,Xu CJ,Xu SF.Advances in risk factors for recurrence of common bile duct stones[J].Int J Med Sci,2021,18(4):1067-1074.
- [5] Kozyk M,Giri S,Harindranath S,et al.Recurrence of common bile duct stones after endoscopic clearance and its predictors:a systematic review[J].DEN Open,2024,4(1):e294.
- [6] Han JY,Wu SD,Fan Y,et al.Biliary microbiota in choledocholithiasis and correlation with duodenal microbiota[J].Front Cell Infect Microbiol,2021,11:625589.
- [7] 赵健楠,范莹,吴硕东.胆囊Cajal样间质细胞与胆囊胆固醇结石形成关系的研究进展[J].医学综述,2019,25(21):4180-4184,4190.
- [8] Ye C,Zhou WC,Zhang H,et al.Alterations of the bile microbiome in recurrent common bile duct stone[J].Biomed Res Int,2020,2020:4637560.
- [9] Zhang Q,Ye M,Su W,et al.Sphincter of Oddi laxity alters bile duct microbiota and contributes to the recurrence of choledocholithiasis[J].Ann Transl Med,2020,8(21):1383.
- [10] Liu Q,Zheng LY,Wang Y,et al.Primary choledocholithiasis occurrence and recurrence is synergetcally modulated by the bile microbiome and metabolome alternations[J].Life Sci,2023,331:122073.
- [11] El Kasmi KC,Vue PM,Anderson AL,et al.Macrophage-derived IL-1β/NF-κB signaling mediates parenteral nutrition-associated cholestasis[J].Nat Commun,2018,9(1):1393.
- [12] 张召,王玲玲,吕婷,等.胆总管结石患者胆汁中性粒细胞胞外诱捕网激活水平及其临床意义探讨[J].实用肝脏病杂志,2024,27(5):781-784.
- [13] Sun DY,Niu ZM,Zheng HX,et al.A mitochondrial DNA variant elevates the risk of gallstone disease by altering mitochondrial function[J].Cell Mol Gastroenterol Hepatol,2021,11(4):1211-1226.e15.
- [14] Hou HY,Jiang ZY,Zhu LY.The multi-omics insights into mitochondrial dysfunction in the pathogenesis of cholelithiasis[J].Medicine,2025,104(37):e44525.
- [15] Yan WL,Zhang K,Guo J,et al.Bile acid-mediated gut-liver axis crosstalk:the role of nuclear receptor signaling in dynamic regulation of inflammatory networks[J].Front Immunol,2025,16:1595486.
- [16] Guan YP,Zhang EC,Zhang C,et al.Bile acid profiles in choledocholithiasis and their ability to predict common bile duct stone recurrence after endoscopic retrograde cholangiopancreatography treatment[J].J Hepatobiliary Pancreat Sci,2023,30(6):755-766.
- [17] Hu H,Shao WT,Liu Q,et al.Gut microbiota promotes cholesterol gallstone formation by modulating bile acid composition and biliary cholesterol secretion[J].Nat Commun,2022,13(1):252.
- [18] Grigor'eva IN,Romanova TI.Gallstone disease and microbiome[J].Microorganisms,2020,8(6):835.
- [19] Zhang MM,Wu X,Wu DS,et al.Long-term prognosis and risk factors associated with 30-day unplanned repeated ERCP in patients with common bile duct stones[J].Ther Adv Gastroenterol,2025,18:17562848251342342.
- [20] Manes G,Paspatis G,Aabakken L,et al.Endoscopic management of common bile duct stones:European Society of Gastrointestinal Endoscopy(ESGE)guideline[J].Endoscopy,2019,51(5):472-491.
- [21] Wang SF,Wu CH,Sung KF,et al.Multi-center study of the association between serum lipid levels and recurrent common bile duct stone after endoscopic retrograde cholangiopancreatography with propensity score matching analysis[J].Dig Dis Sci,2026,71(6):2271-2282.
- [22] 叶绿望,王丛,范俊维,等.基于FXR-FGF19通路研究益生菌对胆总管结石患者胆汁酸代谢的影响[J].胃肠病学,2024,29(1):10-14.
- [23] 周东海,刘京山.腹腔镜胆总管探查术与内镜十二指肠乳头括约肌切开术后胆总管结石复发率比较[J].中国内镜杂志,2026,32(2):58-62.
- [24] 中国医疗保健国际交流促进会,中西医结合脾胃病分会.胆结石中西医协同诊疗共识意见[J].世界中医药,2026,21(9):1557-1574.
- [25] 张曦,冯钟煦,范鹏,等.大柴胡汤加减对胆总管结石患者术后结石复发的影响[J].现代中西医结合杂志,2024,33(17):2456-2460.
- [26] 舒亚倩,张琦,齐伟,等.ERCP联合EPBD序贯中药治疗肝外胆管结石术后肝郁气滞型患者60例临床观察[J].中医药临床杂志,2025,37(2):374-379.
- [27] 孟维山,苏忠,吴维兴,等.消炎利胆汤联合熊去氧胆酸对经胆囊管胆总管探查取石术治疗胆总管结石患者术后的疗效分析[J].中国中西医结合外科杂志,2025,31(4):555-559.
- [28] 李凡,沈毅慧.枯草杆菌二联活菌肠溶胶囊联合胆宁片对胆总管结石ERCP术后结石复发的预防效果[J].临床合理用药,2026,19(17):28-33.
- [29] 徐绍恒.清热利胆颗粒对胆总管结石ERCP取石术后临床疗效分析及胆汁酸代谢影响[D].大连:大连医科大学,2024.
- [30] 王晓,方勇,何聪,等.郁茵利胆颗粒预防内镜逆行胰胆管造影术术后胆总管结石复发的临床观察[J].中国实验方剂学杂志,2026,32(4):159-166.
- [31] 韦慧怡,庞浇安,罗艳萍,等.基于SCF/c-Kit信号轴探讨大黄灵仙方对肝内胆管炎大鼠炎症反应的影响[J].中成药,2026,48(6):1866-1874.
- [32] 舒亚倩.十二味疏肝利胆颗粒对肝胆管结石术后临床疗效及盐酸林可霉素致豚鼠色素性结石的影响[D].合肥:安徽中医药大学,2025.
- [33] Wang W,Zhang K,Liu B,et al.Chaihu Shugan prevents cholesterol gallstone formation by ameliorating the microbiota dysbiosis and metabolic disturbance in mice[J].Front Pharmacol,2023,14:1291236.
- [34] 黄家望,俞赟丰,黎柳,等.从“脾为之卫”理论探讨肠道菌群在代谢性炎症中的作用[J].湖南中医药大学学报,2025,45(8):1518-1526.
- [35] 王俊鹏,陈龙畅,杨莹,等.基于“胆汁酸-肠道菌群”轴探讨胆固醇结石“土壅木郁”病机的生物学内涵[J].中国医药导报,2025,22(22):115-118.
- [36] 刘雪娇,贾越博,杨珂鸣,等.基于气学理论与线粒体能量学关系探讨胃肠动力障碍疾病的病理机制[J].上海中医药杂志,2024,58(5):14-18,32.
- [37] 尹晓岚,马祥雪,张北华,等.健脾中药复方治疗脾虚证作用机制研究现状与展望[J].世界科学技术-中医药现代化,2024,26(3):669-674.
- [38] 李双翼,时昭红,张书,等.从脾与Cajal间质细胞关系探讨中医药治疗功能性消化不良的作用机制[J].安徽中医药大学学报,2026,45(4):9-13.
- [39] 辛萍,付滨.从中医之“卫”论自身免疫性疾病[J].中医临床研究,2025,17(24):37-43.
- [40] 肖定洪,王庆其.王庆其“脾主黏膜”学术观点及其在胃肠疾病治疗中的应用[J].中医杂志,2017,58(15):1278-1282.
- [41] 卞昊宇,张立平,王惠临.初发、复发型胆总管结石患者中医证候的回顾分析[J].辽宁中医杂志,2023,50(6):23-28.
- [42] 王惠临,张立平,卞昊宇,等.利胆消石合剂对胆总管结石患者ERCP术后胆汁成分影响的临床研究[J].天津中医药大学学报,2023,42(3):280-285.
- [43] 魏骄阳,王林恒,姚玉璞,等.利胆消石合剂对肝郁脾虚型胆总管结石患者术后复发的预防效果观察[J].北京中医药,2026,45(3):338-343.
- [44] 莫翠毅.胆汁胃蛋白酶原检测对内镜下乳头括约肌切开术后肠胆反流的诊断价值[J].检验医学与临床,2017,14(23):3539-3541.
- [45] 卞昊宇,韩冉,段学光,等.运用复发型胆总管结石患者胆道细菌建立豚鼠胆石症模型[J].河北医学,2024,30(1):40-45.
- [46] 卞昊宇,吕福琪,魏骄阳,等.探究利胆消石合剂预防内镜下逆行性胰胆管造影术术后胆总管结石复发的作用机制[J].辽宁中医药大学学报,2025,27(5):9-16.
- [47] 吕福琪,卞昊宇,魏骄阳,等.基于16S rDNA测序技术研究利胆消石合剂对胆石症豚鼠模型肠道菌群的影响[J].北京中医药,2025,44(10):1275-1284.
- [48] 吕福琪,卞昊宇,魏骄阳,等.利胆消石合剂对胆总管结石模型豚鼠血清胃肠激素及胆道组织中Cajal样间质细胞的影响[J].中医杂志,2025,66(17):1793-1800.